Publication at First Faculty of Medicine |
2020
Abstract
KRAS (Kirsten rat sarcoma viral oncogene homolog) mutations are the most frequently oncogene aberrations in non-small cell lung cancer (NSCLC). KRAS-mutated NSCLC represents a heterogeneous subgroup because there are different KRAS subtypes, mutations and comutations.
It results in different biological behavior of the tumor and its response to treatment. A large majority of patients with KRAS mutations have short-term survival.
Trials for targeted treatment have failed. Immunotherapy is the most promising treatment for some patients with KRAS-mutated NSCLC.
A very hopeful is an experimental cancer drug AMG 510 which is tested in phase 1/2 clinical trial.